

TABLE OF CONTENTS

SUMMARY OF POLICY CONSIDERATIONS FROM THE NY'98 WORKSHOP	9
---	----------

Part I. Transplantation

1. INTERNATIONAL TRANSPLANTATION ISSUES: PROBLEMS AND NEEDS	15
The core of the problem: the shortage of organ donors.....	15
Can the organ procurement gap be narrowed?	18
2. IMMUNOLOGICAL HURDLES FOR TRANSPLANTATION	20
Current methods to prevent rejection	23
New immunosuppressive drugs.....	23
Infections in organ transplant recipients on immunosuppressive treatment	25
3. NEW APPROACHES TO INDUCE TOLERANCE	26
Inbred miniature swine and cloning	27

Part II. Xenotransplantation

1. A HISTORICAL PERSPECTIVE	31
2. PIGS AS ORGAN DONORS.....	32
Science: perspectives and issues	32
Will pig organs be physiologically capable of supporting prolonged human life?.....	33
Infectious risk: What precautions should be taken to avoid the transfer of porcine pathogens?	34
Micro-organisms that pigs may harbour.....	36
3. BABOONS AS ORGAN DONORS	37
What is the risk of infectious disease when performing baboon-to-man transplants?.....	38

Part III. International Policy Issues in Xenotransplantation

1. HANDLING THE RISK: THE CHALLENGE OF INTERNATIONAL SURVEILLANCE	43
Notification systems	43
Registry systems	44
Archive systems.....	44
2. INTERNATIONAL CO-OPERATION	46
Current developments on national and international draft guidelines on xenotransplantation	51
3. LESSONS LEARNED IN GENE THERAPY	58

4. INDUSTRY INVOLVEMENT.....	60
5. ECONOMIC ASPECTS.....	63
6. SOCIO-LEGAL AND ETHICAL ASPECTS.....	64
Legal issues.....	64
Ethical issues	66
Animal welfare and husbandry.....	67
Public perception	69
Developing countries.....	71
Patient monitoring	72
CONCLUDING CONSIDERATIONS	73
What is the actual economic burden to society of diseases where xenotransplantation may have a role?	73
What are the options today to alleviate organ shortage? What are the options today to alleviate the burden of disease where xenotransplantation may have a role?.....	74
What are the options for treatment derived from recent technological advances?	74
What public health tools are there to reduce or eliminate the risk of transmission of infectious agents?	74
What are the key features of an international framework to detect, identify, monitor, evaluate and manage zoonotic risk?.....	76
What can we learn from the international regulatory experience on gene therapy?	77
How can the OECD and other international organisations assist the development of international public health tools?.....	77
What can we learn about animal welfare and about accessibility, equity and acceptance in the context of xenotransplantation?.....	78
What are the salient features that prevent the adoption of xenotransplantation? What are the research gaps that must be addressed to move the field forward?	80
<i>Annex I</i> Working Party on Xenografts (of The Nuffield Council on Bioethics): Summary of Recommendations	83
<i>Annex II</i> Article 152 of the Amsterdam Treaty (ex Article 129).....	86
<i>Annex III</i> Recommendation of the Council of Europe.....	87
<i>Annex IV</i> Workshop on Transplantations, Including Xenotransplantations: Proposed Strategy for Developing Research into and Accessibility to these Technologies in Africa and the Third World ...	88
<i>Annex V</i> Joint OECD-New York Academy of Sciences Workshop Programme.....	89
<i>Annex VI</i> Steering and Expert Group for the Preparation of the OECD Workshop New York '98 ..	102
References	107

List of Figures

1. Size of the waiting list and number of transplant recipients in the United States 16
2. Size of the waiting list and number of kidney transplant recipients in the United Kingdom and the Republic of Ireland..... 16
3. Size of the waiting list and number of kidney transplant recipients in France..... 17

List of Tables

1. International data on organ donation in 1997 17
2. Organ donation and transplantation figures for Spain, 1990-97..... 20
3. One-, two- and four-year graft and patient survival rates in the United States, by organ, October 1987-December 1995 21
4. Classification of selected traditional and new immunosuppressive drugs according to their mode of action in different phases of the activation of the immune response 24

List of Boxes

1. The Spanish experience 19
2. What's in a registry? 44
3. Biotrack Online..... 46
4. WHO frameworks for monitoring infectious diseases 47
5. Network for the epidemiological surveillance and control of communicable diseases in the European Community 49
6. Role of the Office International des Épidémiologies in the surveillance of zoonoses and in the control of trade in animals and animal products..... 66
7. Public policy development and public confidence 70